Review
Open access
Oct 2026
Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors
Thromboembolic diseases impose a significant burden on global health. However, the currently approved anticoagulant drugs, including heparin, vitamin K antagonists, and direct oral anticoagulants (DOACs), all carry certain bleeding risks. The proteases inhibited by these drugs play crucial roles in both pathological th...
Hui Yuan, Yuan-Yuan He, Mao Zhang et al.
· Frontiers in Immunology · 0 citations